2022
Evaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis
Tucker M, Azar MM, Cohen E, Gan G, Deng Y, Palacios C, Malinis M. Evaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis. Transplant Infectious Disease 2022, 24: e13876. PMID: 35684932, PMCID: PMC9348300, DOI: 10.1111/tid.13876.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsSARS-CoV-2 infectionOrgan transplant recipientsCritical COVID-19Clinical effectivenessTransplant recipientsVaccine eraVaccinated solid organ transplant recipientsCOVID-19Propensity score-matched cohortSARS-CoV-2 vaccinationSevere coronavirus disease 2019Cause-specific Cox regression modelsCOVID-19-related mortalitySARS-CoV-2 vaccinesSARS-CoV-2 infection ratesCurrent vaccine recommendationsKey preventative strategiesPrimary vaccine seriesRetrospective cohort studyDoses of mRNACox regression modelCoronavirus disease 2019Poisson regression modelsVaccine series
2021
Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7
2020
Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer
Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.Peer-Reviewed Original ResearchConceptsCell lung cancerGeneral patientsNSCLC populationLung cancerCox proportional hazards modelYale-New Haven HospitalGeneral NSCLC populationOutcomes of patientsOverall median survivalRetrospective cohort studyPredictors of survivalKaplan-Meier curvesHIV-1 RNACopies/mLLog-rank testProportional hazards modelNew Haven HospitalCancer treatment regimensMedian CD4Antiretroviral therapyCohort studyMedian survivalOverall survivalHIV infectionMedian ageAdoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDeathHumansImmune Checkpoint InhibitorsLung NeoplasmsRetrospective StudiesConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patterns
2019
HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort.
Ekong UD, Antala S, Bow L, Sese D, Morotti R, Rodriguez-Davalos M, Gan G, Deng Y, Emre SH. HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort. Experimental And Clinical Transplantation 2019, 17: 6-17. PMID: 30777518, PMCID: PMC11165937, DOI: 10.6002/ect.mesot2018.l30.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsChildChild, PreschoolConnecticutFemaleGraft RejectionGraft SurvivalHistocompatibilityHistocompatibility TestingHLA AntigensHumansImmunosuppressive AgentsInfantIsoantibodiesLiver TransplantationMaleRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeYoung AdultConceptsDonor-specific antibodiesEpitope mismatchesMismatch loadAcute rejectionClass II donor-specific antibodiesDQ lociDQ Donor-Specific AntibodiesNon-HLA antibodiesAntibody-mediated rejectionPediatric liver transplantationSingle-center cohortHLAMatchmaker softwareImmunosuppression strategiesLiver transplantLiver transplantationAllograft fibrosisEplet mismatchesLiver biopsyPediatric patientsFibrosis scoreHLA-DRRetrospective reviewTransplant physiciansHLA-DQHLA-DQB1